Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...

Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed last Friday at $2.90.Invest ...

Today, we will plunge into the realm of sportswear logos. The top 10 brands will be ranked according to how much they have affected this business. What comes to mind when you think about sportswear?

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for ...

Absci Co. (NASDAQ:ABSI – Get Free Report) has been assigned an average recommendation of “Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports.

Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design ...

Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class ...

Absci Corporation and Owkin have announced a partnership to combine their advanced AI platforms for the rapid discovery and design of novel therapeutics. Absci, known for its generative AI in drug ...

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to ...

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock ...